Compare ARK Genomic Revolution ETF (ARKG) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs CSX Corporation — how do they compare? ARK Genomic Revolution ETF trades at $40.56, while CSX Corporation trades at $49.82 (market cap $91.81B). The key difference: CSX Corporation pays a 1.13% dividend while ARK Genomic Revolution ETF pays none, and CSX Corporation is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | CSX | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $49.41 |
52-Week Low | $23.09 | $32.05 |
Market Cap | — | $91.81B |
Enterprise Value | — | $110.04B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
CSX trades at $49.41, slightly above the consensus price target of $48.21, with a 0.12% daily gain. The technical outlook is bullish based on moving averages, though RSI levels suggest overbought conditions. Recent earnings have shown mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $14.9B in 2022 to $14.1B in 2025. The company maintains strong profitability with a 21.55% net income margin and recently announced a $0.14 dividend payable in June 2026.
The stock faces headwinds from declining revenue and high valuation multiples (P/E of 30.31), but analyst sentiment remains positive with 56.52% buy ratings. Key risks include freight demand volatility and elevated debt levels. Upside potential exists if operational improvements and margin expansion initiatives succeed, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
